Regulation of MHC class I membrane expression by β2-microglobulin

Ussama M. Abdel-Motal, X. Zhou, A. R. Siddiqi, M. Jondal

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

MHC-I binding peptides and β2 microglobulin (β2-m) can upregulate the MHC-1 heavy chain expression on certain peptide transporter mutant cells. We have further studied this with normal cells and nonmutant cell lines. No MHC-I upregulation was seen with normal, resting or activated T cells. On mouse cell lines P815 and B16, both peptides and human β2-m gave an additive upregulation response. With the human small cell lung carcinoma H82, an optimal HLA.A2 binding peptide (GILGFVFTL) gave an upregulation response, whereas β2-m alone or in combination with this peptide had no effect. However, β2-m potentiated the response of H82 cells to a slightly longer peptide. Using mutant RMA-S cells, it was found that both Brefeldin A (BFA) and chloroquine, but not leupeptin, inhibited MHC-I upregulation response to both peptide and β2-m. In contrast to chloroquine, BFA also gave a reduction of background membrane MHC-I expression, presumably due to a block in Golgi transport. Human β2-m, which binds to RMA-S cells, and which is known to internalize into endosomes, did not reappear on the cell surface. When D(b) on RMA-S cells was upregulated by human β2-m, the sensitivity of these cells to D(b) restricted CTL cells increased. Even if β2-m did not upregulate the overall MHC-I expression on normal cells, it may still quantitatively increase the expression of optimally presented peptides and endosomal recycling may be important in this process.

Original languageEnglish
Pages (from-to)395-400
Number of pages6
JournalScandinavian Journal of Immunology
Volume38
Issue number4
Publication statusPublished - 1993
Externally publishedYes

Fingerprint

Membranes
Up-Regulation
Peptides
Brefeldin A
Chloroquine
Cell Line
Endosomes
Small Cell Lung Carcinoma
T-Lymphocytes

ASJC Scopus subject areas

  • Immunology

Cite this

Regulation of MHC class I membrane expression by β2-microglobulin. / Abdel-Motal, Ussama M.; Zhou, X.; Siddiqi, A. R.; Jondal, M.

In: Scandinavian Journal of Immunology, Vol. 38, No. 4, 1993, p. 395-400.

Research output: Contribution to journalArticle

Abdel-Motal, Ussama M. ; Zhou, X. ; Siddiqi, A. R. ; Jondal, M. / Regulation of MHC class I membrane expression by β2-microglobulin. In: Scandinavian Journal of Immunology. 1993 ; Vol. 38, No. 4. pp. 395-400.
@article{da03d93b3b854857ab2441a7cb315d22,
title = "Regulation of MHC class I membrane expression by β2-microglobulin",
abstract = "MHC-I binding peptides and β2 microglobulin (β2-m) can upregulate the MHC-1 heavy chain expression on certain peptide transporter mutant cells. We have further studied this with normal cells and nonmutant cell lines. No MHC-I upregulation was seen with normal, resting or activated T cells. On mouse cell lines P815 and B16, both peptides and human β2-m gave an additive upregulation response. With the human small cell lung carcinoma H82, an optimal HLA.A2 binding peptide (GILGFVFTL) gave an upregulation response, whereas β2-m alone or in combination with this peptide had no effect. However, β2-m potentiated the response of H82 cells to a slightly longer peptide. Using mutant RMA-S cells, it was found that both Brefeldin A (BFA) and chloroquine, but not leupeptin, inhibited MHC-I upregulation response to both peptide and β2-m. In contrast to chloroquine, BFA also gave a reduction of background membrane MHC-I expression, presumably due to a block in Golgi transport. Human β2-m, which binds to RMA-S cells, and which is known to internalize into endosomes, did not reappear on the cell surface. When D(b) on RMA-S cells was upregulated by human β2-m, the sensitivity of these cells to D(b) restricted CTL cells increased. Even if β2-m did not upregulate the overall MHC-I expression on normal cells, it may still quantitatively increase the expression of optimally presented peptides and endosomal recycling may be important in this process.",
author = "Abdel-Motal, {Ussama M.} and X. Zhou and Siddiqi, {A. R.} and M. Jondal",
year = "1993",
language = "English",
volume = "38",
pages = "395--400",
journal = "Scandinavian Journal of Immunology",
issn = "0300-9475",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Regulation of MHC class I membrane expression by β2-microglobulin

AU - Abdel-Motal, Ussama M.

AU - Zhou, X.

AU - Siddiqi, A. R.

AU - Jondal, M.

PY - 1993

Y1 - 1993

N2 - MHC-I binding peptides and β2 microglobulin (β2-m) can upregulate the MHC-1 heavy chain expression on certain peptide transporter mutant cells. We have further studied this with normal cells and nonmutant cell lines. No MHC-I upregulation was seen with normal, resting or activated T cells. On mouse cell lines P815 and B16, both peptides and human β2-m gave an additive upregulation response. With the human small cell lung carcinoma H82, an optimal HLA.A2 binding peptide (GILGFVFTL) gave an upregulation response, whereas β2-m alone or in combination with this peptide had no effect. However, β2-m potentiated the response of H82 cells to a slightly longer peptide. Using mutant RMA-S cells, it was found that both Brefeldin A (BFA) and chloroquine, but not leupeptin, inhibited MHC-I upregulation response to both peptide and β2-m. In contrast to chloroquine, BFA also gave a reduction of background membrane MHC-I expression, presumably due to a block in Golgi transport. Human β2-m, which binds to RMA-S cells, and which is known to internalize into endosomes, did not reappear on the cell surface. When D(b) on RMA-S cells was upregulated by human β2-m, the sensitivity of these cells to D(b) restricted CTL cells increased. Even if β2-m did not upregulate the overall MHC-I expression on normal cells, it may still quantitatively increase the expression of optimally presented peptides and endosomal recycling may be important in this process.

AB - MHC-I binding peptides and β2 microglobulin (β2-m) can upregulate the MHC-1 heavy chain expression on certain peptide transporter mutant cells. We have further studied this with normal cells and nonmutant cell lines. No MHC-I upregulation was seen with normal, resting or activated T cells. On mouse cell lines P815 and B16, both peptides and human β2-m gave an additive upregulation response. With the human small cell lung carcinoma H82, an optimal HLA.A2 binding peptide (GILGFVFTL) gave an upregulation response, whereas β2-m alone or in combination with this peptide had no effect. However, β2-m potentiated the response of H82 cells to a slightly longer peptide. Using mutant RMA-S cells, it was found that both Brefeldin A (BFA) and chloroquine, but not leupeptin, inhibited MHC-I upregulation response to both peptide and β2-m. In contrast to chloroquine, BFA also gave a reduction of background membrane MHC-I expression, presumably due to a block in Golgi transport. Human β2-m, which binds to RMA-S cells, and which is known to internalize into endosomes, did not reappear on the cell surface. When D(b) on RMA-S cells was upregulated by human β2-m, the sensitivity of these cells to D(b) restricted CTL cells increased. Even if β2-m did not upregulate the overall MHC-I expression on normal cells, it may still quantitatively increase the expression of optimally presented peptides and endosomal recycling may be important in this process.

UR - http://www.scopus.com/inward/record.url?scp=0027358724&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027358724&partnerID=8YFLogxK

M3 - Article

C2 - 8211001

AN - SCOPUS:0027358724

VL - 38

SP - 395

EP - 400

JO - Scandinavian Journal of Immunology

JF - Scandinavian Journal of Immunology

SN - 0300-9475

IS - 4

ER -